TISLELIZUMAB
Clinical trials for TISLELIZUMAB explained in plain language.
Never miss a new study
Get alerted when new TISLELIZUMAB trials appear
Sign up with your email to follow new studies for TISLELIZUMAB, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New triple therapy hopes to outsmart tough esophageal cancer
Disease control Not yet recruitingThis study tests a new three-drug combination for people with advanced esophageal squamous cell carcinoma (ESCC). The drugs include a targeted therapy (becotatug vedotin), an immunotherapy (tislelizumab), and standard chemotherapy. The goal is to see if this combo shrinks tumors …
Matched conditions: TISLELIZUMAB
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
New combo therapy aims to turn inoperable lung cancer into a curable disease
Disease control Not yet recruitingThis study tests a new approach for people with stage III non-small cell lung cancer that cannot be removed with surgery. Participants receive a combination of an immunotherapy drug (tislelizumab), standard chemotherapy, and a targeted procedure that delivers chemotherapy directl…
Matched conditions: TISLELIZUMAB
Phase: PHASE2 • Sponsor: Sichuan Cancer Hospital and Research Institute • Aim: Disease control
Last updated May 26, 2026 08:32 UTC